Author

PJ Stella

Institutions: Fox Chase Cancer Center, Albert Einstein College of Medicine, Kaiser Permanente, University of Pittsburgh, Baylor College of Medicine, Virginia Commonwealth University, Dana-Farber Cancer Institute, Michigan Cancer Research Consortium, UPMC Hillman Cancer Center, Stanford Medicine, Dan L Duncan Comprehensive Cancer Center, VCU Massey Comprehensive Cancer Center, The Ohio State University

Observed institutions: Fox Chase Cancer Center, Albert Einstein College of Medicine, Carle Foundation Hospital, Mayo Clinic, Kaiser Permanente, University of Pittsburgh, Baylor College of Medicine, Virginia Commonwealth University, Missouri Valley Cancer Consortium, Dana-Farber Cancer Institute, Michigan Cancer Research Consortium, Mayo Clinic in Arizona, UPMC Hillman Cancer Center, Stanford Medicine, Mayo Clinic in Florida, Dan L Duncan Comprehensive Cancer Center, VCU Massey Comprehensive Cancer Center, The Ohio State University

OpenAlex ID: A5111546165

Abstract S3-06: A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG Oncology/NSABP B-52

2017 · MF Rimawi, RS Cecchini, et al. · Cancer Research · 41

Abstract S1-02: PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy

2017 · NS Kornblum, J Manola, et al. · Cancer Research · 35

Tolerability of lapatinib given concurrently with paclitaxel and trastuzumab as part of adjuvant therapy in patients with resected HER2+ breast cancer: initial safety data from the Mayo Clinic cancer research consortium trial RC0639.

2009 · BS Johnson, AC Dueck, et al. · Cancer Research · 2

Abstract P1-12-06: N0937 (Alliance): Preliminary results of a phase II clinical trial of cisplatin and the novel agent brostallicin in patients with metastatic triple negative breast cancer (mTNBC)

2012 · A Moreno-Aspitia, KM Rowland, et al. · Cancer Research

OT3-01-14: N0937: Phase II Trial of Brostallicin and Cisplatin in Patients with Metastatic Triple Negative Breast Cancer.

2011 · A Moreno-Aspitia, KM Rowland, et al. · Cancer Research

Works count: 5

Citation count: 78

H-index: 2

I10-index: 2